AR 67

Drug Profile

AR 67

Alternative Names: (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin; AR-67; D 67; DB-67

Latest Information Update: 21 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Pittsburgh
  • Developer Arno Therapeutics; TaiGen Biotechnology; TTY Biopharm
  • Class Antineoplastics; Camptothecins; Organosilicon compounds
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Glioblastoma; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 30 Sep 2016 Vivacitas Oncology acquires AR 67 from Arno Therapeutics
  • 18 May 2012 Arno Therapeutics terminates its licence for AR 67 (Arno Therapeutics Form-10K report May 2012)
  • 01 May 2012 Discontinued - Phase-I for Solid tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top